Urologix' T3 system receives CE-marking:
This article was originally published in Clinica
Executive Summary
Urologix' transurethral thermoablation therapy T3 system has received European certification for CE-marking (see Clinica No 706, p 16). The T3 system is a non-surgical, anaesthesia-free, catheter-based treatment for benign prostatic hyperplasia, which is estimated to affect over 23 million men worldwide with more than $8,000 million spent annually on treatment.